These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 10426453

  • 1. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
    Nabholtz JM.
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
    [Abstract] [Full Text] [Related]

  • 2. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA.
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [Abstract] [Full Text] [Related]

  • 3. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
    Nabholtz JM, North S, Smylie M, Mackey J, Au HJ, Au R, Morrish D, Salter E, Tonkin K.
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):11-8. PubMed ID: 10810933
    [Abstract] [Full Text] [Related]

  • 4. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting.
    Nabholtz JM, Tonkin K, Smylie M, Mackey J, Janowska-Wieczorek A.
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):10-6. PubMed ID: 10203265
    [Abstract] [Full Text] [Related]

  • 5. Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
    Dieras V.
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):18-22. PubMed ID: 9865707
    [Abstract] [Full Text] [Related]

  • 6. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA.
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [Abstract] [Full Text] [Related]

  • 7. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D, Antoine E.
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE, Anderson SJ, Brown A, Scholnik AP, Desai AM, Kardinal CG, Lembersky BC, Mamounas EP.
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [Abstract] [Full Text] [Related]

  • 9. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
    Sparano JA.
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):14-9. PubMed ID: 10426454
    [Abstract] [Full Text] [Related]

  • 10. Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer.
    Nabholtz JM, Smylie M, Mackey J, Au HJ, Tonkin K, Au R, Morrish D, Salter E.
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):47-52. PubMed ID: 10403474
    [Abstract] [Full Text] [Related]

  • 11. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA, Fields S, Peacock N.
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [Abstract] [Full Text] [Related]

  • 12. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
    Crown J.
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
    [Abstract] [Full Text] [Related]

  • 13. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
    Costa SD, von Minckwitz G, Raab G, Blohmer JU, Dresel V, Eidtmann H, Hilfrich J, Jackisch C, Merkle E, Gademann G, Kaufmann M.
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
    [Abstract] [Full Text] [Related]

  • 14. Recent progress in the clinical development of docetaxel (Taxotere).
    Hortobagyi GN.
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
    [Abstract] [Full Text] [Related]

  • 15. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
    Valero V, Perez E, Dieras V.
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):15-23. PubMed ID: 11552226
    [Abstract] [Full Text] [Related]

  • 16. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM, Smylie M, Mackey JR, Noel D, Paterson AH, al-Tweigeri T, Au D, Sansregret E, Delorme F, Riva A.
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [Abstract] [Full Text] [Related]

  • 17. Taxane-based three-drug combination in metastatic and adjuvant treatment of breast cancer.
    Nabholtz JM, Mackey J, Smylie M, Tonkin K.
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):27-31. PubMed ID: 9865709
    [Abstract] [Full Text] [Related]

  • 18. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
    Aapro M.
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
    [Abstract] [Full Text] [Related]

  • 19. Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.
    Aapro MS.
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):17-21. PubMed ID: 10203266
    [Abstract] [Full Text] [Related]

  • 20. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J.
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.